Oral Balsalazide (Colazal) For Ulcerative Colitis
Balsalazide disodium (Colazal), a prodrug of mesalamine, was marketed in the US this year for oral treatment of mildly to moderately active ulcerative colitis. Oral formulations of mesalamine have been available in the US for nine years for treatment and maintenance of remissions and olsalazine, which is a dimer of mesalamine, is marketed for maintenance of remissions but not for treatment. Balsalazide has been available in Europe for four years....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Oral Balsalazide (Colazal) For Ulcerative Colitis
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1109
Article Code: 1109b
Date: July 23, 2001
Volume: 43
Pages: 62-63
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1109
Article Code: 1109b
Date: July 23, 2001
Volume: 43
Pages: 62-63
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)